Novartis has discontinued a phase 2‑stage radioligand therapy (RLT) candidate, Lutetium‑NeoB (Lu‑NeoB), after early clinical data failed to support further development; the decision was not due to safety issues and ongoing patients remain on protocol.
The company maintains a broad radioligand pipeline with multiple RLTs in phase 1 across targets such as DLL3, HER2, and FAP, plus at least one FAP‑directed candidate in phase 2.
CEO Vas Narasimhan has publicly stated that Novartis’s commitment to the radioligand therapy modality is 'completely unchanged,' underscoring continued investment in RLTs despite this candidate’s termination.
Sources:
Novartis drops phase 2 radioligand therapy, but CEO's ...
Novartis axes osteoarthritis asset and radioligand therapy
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine ...
JPM24: As cancer players jump head-first into ADC field ...
NOVARTIS AKTIEN News | 904278 Nachrichten - Finanznachrichten
Earnings call transcript: Novartis sees strong Q1 2025 ...
Novartis opens new radioligand therapy manufacturing ...
[PDF] Report on Nonfinancial Matters 2025 | Novartis
Novartis provides update on production of radioligand ...
Novartis cuts 10% of R&D projects in 'focused' strategy
Novartis resumes production of radioligand therapy medicines
Novartis resumes production of radioligand therapy ...
Novartis to build radioligand therapy site in Texas to expand US manufacturing